Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
CRANBURY, N.J., April 16, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today...
-
CRANBURY, N.J., March 7, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, announced today the...
-
CRANBURY, N.J., March 1, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD) announced today the pricing of an underwritten offering of 10,000,000 shares of its common stock at a price of...
-
CRANBURY, N.J., March 1, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced it has commenced an underwritten public offering of its common stock. Leerink Swann LLC and Cowen...
-
CRANBURY, N.J., Feb. 28, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the...
-
Phase 3 Results of Migalastat HCl Monotherapy for Fabry Disease Expected in 3Q12 Multiple Chaperone-Enzyme Replacement Therapy (ERT) Combination Programs Advancing Positive Phase 2...
-
CRANBURY, N.J., Feb. 13, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, recently presented updated...
-
CRANBURY, N.J., Feb. 10, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the...
-
CRANBURY, N.J., Feb. 9, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, presented preclinical...
-
CRANBURY, N.J., Feb. 7, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the receipt...